



Elenco Oral Communications

ID	N. pgm	Title	Presenting Author
15/06/2023 10.05 - 11.05 Emerging immunological and virological concepts in viral hepatitis			
62	OC 1	Ultrasensitive HBV-RNA quantification as a promising biomarker to optimize the staging of chronic HBV infection and to detect minimal viral activity under prolonged virological suppression and occult HBV infection	Lorenzo Piermatteo, Roma
340	OC 2	Functional and transcriptional restoration of exhausted virus-specific T lymphocytes from patients with chronic hepatitis B	Camilla Ceccatelli Berti, Parma
164	OC 3	HDV viral decline in HIV-infected and uninfected subjects with HBV/HDV-related cirrhosis during "real world" bulevirtide compassionate use program at INMI Spallanzani in Rome, Italy	Chiara Taibi, Roma
177	OC 4	Successful treatment of resistant HCV in ten patients, failed for other DAA, with glecaprevir/pibrentasvir and sofosbuvir	Manuela Migliorati, Brescia
15/06/2023 10.05 - 11.05 Epidemiology trends in infections			
54	OC 5	HIV-1 Transmitted Drug Resistance in Newly Diagnosed Individuals in Italy Over the Period 2015-2021	Lavinia Fabeni, Roma
284	OC 6	Genomic epidemiology of the main SARS-CoV-2 variants circulating in Italy in 2020 and 2021 period	Annalisa Bergna, Milano
108	OC 7	Trends of testing for HIV and syphilis in community based voluntary counselling and testing (CBVCT) services in the period 2019-2022: are there people more at risk?	Alessandro Soria, Monza
437	OC 8	Epidemiological and perceived health status determinants of early access to vaccine in Latium region Mpox vaccination (MpoxV) campaign	Giulia Del Duca, Roma
15/06/2023 11.10 - 12.10 Immune response in SARS-CoV-2			
290	OC 9	Monocytes and NK cell subsets frequencies after anti-S monoclonal antibodies treatment in COVID-19 patients	Luca Maddaloni, Roma
395	OC 10	ERAPs control In Vitro SARS-CoV-2 Infection by triggering NK and Neutrophil activation	Irma Saulle, Milano
100	OC 11	A novel enhancing effect of SARS-CoV-2 mutations on anti-viral CD8 T cell responses	Camilla Tiezzi, Parma
143	OC 12	Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination	Ilenia Varasi, Siena
15/06/2023 11.10 - 12.10 Inflammation: a major pathogenetic process			
155	OC 13	Effects of cART on residual inflammation and HIV reservoirs in Primary and Chronic HIV infection	Valeria Bono, Milano
532	OC 14	Switching to doravirine reduces chronic inflammation among virologically controlled PLWH: 48 weeks results from the DORAGE cohort	Alessandro Lazzaro, Roma
266	OC 15	Antiretroviral therapy partially restores phenotypic and metabolic immunosenescence features of T cells in HIV infected individuals	Beatrice Dallan, Ferrara
372	OC 16	Human endogenous retroviruses expression correlates with HIV reservoir, lymphocytes activation and low CD4 count in virologically suppressed patients	Vita Petrone, Roma



Elenco Oral Communications

ID	N. pgm	Title	Presenting Author
15/06/2023 12.15 - 13.15 Outcome in first-line regimens			
250	OC 17	Effectiveness of bicitgravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in real-world setting in ART-naïve patients: data from the Icona cohort	Alessandro Tavelli, Milano
313	OC 18	Effectiveness of first-line lamivudine-dolutegravir (3TC-DTG) antiretroviral therapy (ART) in persons living with HIV (PLWH): real-life data from the ICONA Foundation cohort	Sergio Lo Caputo, Foggia
280	OC 19	Body weight and plasma lipids changes in person living with HIV (PLWH) starting double or triple INSTI-based cART regimens	Francesca Bai, Milano
38	OC 20	HIV-DNA decay in ART-naïve PLWH starting dolutegravir plus lamivudine vs triple therapy: 48-week results in a real-life setting	Francesca Lombardi, Roma
15/06/2023 12.15 - 13.15 One size does not fit all			
339	OC 21	Sexual and reproductive unmet clinical needs in Italian women living with HIV: results from Marilyn study	Giulia Valeria Calvino, Roma
265	OC 22	COVID perceptions among pregnant women living in a malaria hyperendemic rural region in Uganda: a cross-sectional study	Francesco Vladimiro Segala, Bari
199	OC 23	Life quality and psychological health of women living with HIV: insight from a single centre in Sassari, Italy	Agnese Colpani, Sassari
226	OC 24	HIV in prison setting: what about inmates? The four-years experience including SARS-CoV2 pandemic period in Florence	Elena Salomoni, Bagno a Ripoli FI
15/06/2023 12.15 - 13.15 Early treatment for COVID-19			
486	OC 25	Incidence and predictors of clinical progression in an early treated COVID-19 multicentric cohort of an Italian Region	Valentina Mazzotta, Roma
311	OC 26	Impact of active and passive SARS-CoV-2 immunization on CAR-T patients: an Italian experience	Federico Frondizi, Roma
420	OC 27	Oral Antivirals against SARS-CoV-2: a Comparison between Molnupiravir and Nirmatrelvir/Ritonavir in a Real Life Setting	Neva Braccialarghe, Roma
522	OC 28	Efficacy, tolerability and prescribing choice in patients undergoing early therapy for COVID19: a single-center 2-years real life experience	Daniela Di Trento, Latina
15/06/2023 13.20 - 14.20 Clinical issues blinking to laboratory			
465	OC 29	Weight gain and loss and stable weight in relation to fat and lean mass in PWH	Nicole Barp, Modena
25	OC 30	Predicting Major Cardiovascular Events in People Living with HIV: a Prospective Observational Study	Emanuele Drappero, Torino
95	OC 31	Long-term CD4+ cells recovery in PLWH on active antiretroviral treatment	Franco Maggiolo, Bergamo
306	OC 32	A comprehensive analysis of total and integrated HIV DNA, CD4 and CD8 T cell response, and survival, quiescence, and stemness signaling at different stages of HIV infection	Letizia Santinelli, Roma
15/06/2023 13.20 - 14.20 Viral infections old and new			
373	OC 33	APRI and FIB-4 scores predict mortality and morbidity in HCV infected subjects after sustained virologic response over the long-term	Gabriele Bruno, Catanzaro
347	OC 34	Common seasonal respiratory viral infections during nine consecutive seasons (2014-2023), including Coronavirus disease (COVID-19) pandemic	Irene Giberti, Genova
288	OC 35	Seroprevalence of Monkeypox (MPX) IgG antibodies in a cohort of PLWH in Rome, during the 2022 outbreak	Pierluigi Francesco Salvo, Roma
52	OC 36	Case series of Monkeypox in a sexual health clinic in Milan	Giacomo Pozza, Milano



Elenco Oral Communications

ID	N. pgm	Title	Presenting Author
15/06/2023 13.20 - 14.20 Preferences limitations and long term outcomes			
189	OC 37	Real world data on PROs and pharmacokinetics in PLWH starting long-acting injectable antiretroviral therapy (LAI-ART)	Daniele Tomasoni, Milano
273	OC 38	Perceived health discrimination and normative stigma: health consequences in a cohort of People living with HIV	Valentina Massaroni, Roma
462	OC 39	Outcome of tenofovir and integrase inhibitors-including ART in PLWH and HBV: data from the SCOLTA cohort	Nicola Squillace, Monza
533	OC 40	Missing data generate missing opportunities: frailty phenotype assessment in the GEPO cohort	Stefania Arsuffi, Brescia
15/06/2023 13.20 - 14.20 Immune response to viruses			
253	OC 41	Humoral and cell-mediated immunity against SARS-CoV-2 in dialysis patients after the vaccination with mRNA-1273 and BNT162b2 vaccines	Maciej Stanislaw Tarkowski, Milano
56	OC 42	Immune response triggered by a candidate vaccine based on a clone of Leishmania tarentolae expressing the SARS-CoV-2 Spike protein	Micaela Garziano, Milano
316	OC 43	Specific T-cell responses to Varicella Zoster Virus glycoprotein E are elicited after vaccination with a recombinant adjuvanted subunit vaccine in patients with multiple sclerosis on immune modulating treatments	Marco Iannetta, Roma
258	OC 44	Interferon and inflammatory response in SARS-CoV-2 infected patients treated with anti-S monoclonal antibodies	Luca Maddaloni, Roma
15/06/2023 13.20 - 14.20 COVID-19 outcome in special population			
171	OC 45	Efficacy of Tixagevimab/Cilgavimab pre-exposure prophylaxis of COVID-19 in severely immunocompromised individuals: data from the OCTOPUS study	Andrea Antinori, Roma
477	OC 46	Outcomes and clinical features of COVID-19 patients with haematological malignancies in the Omicron era	Serena Valeri, Roma
506	OC 47	COVID-19 in PLWH: clinical outcomes, a single center analysis	Chiara Grillo, Foggia
148	OC 48	Molecular characterization of SARS-CoV-2 Omicron clade and clinical presentation in children	Rossana Scutari, Milan
15/06/2023 14.30 - 15.30 Antiviral treatment in COVID-19			
346	OC 49	Prolonged antiviral therapy combined with neutralizing monoclonal antibodies as a treatment strategy for COVID-19 in severely immunocompromised patients during the Omicron wave: a quasi-experimental multicentre cohort study	Carmen Pellegrino, Bari
188	OC 50	Anti-spike monoclonal antibodies to prevent hospitalization in mild COVID-19: final analysis of an observational multicenter study (CONDIVIDIAMO)	Alessandro Soria, Monza
233	OC 51	Clinical efficacy of tixagevimab/cilgavimab pre-exposure prophylaxis in immunocompromised patients treated during Omicron sublineages diffusion. Real life experience from ASST Lecco	Federico Conti, Lecco
444	OC 52	Vaccination and antiviral treatment reduce the time to negative SARS-CoV-2 swab: a real-life study	Giulia Moi, Sassari
15/06/2023 14.30 - 15.30 HIV: much left to do			
140	OC 53	HIV and hospitals: an evolving relationship	Luisa Brogonzoli, Milano
441	OC 54	Achieving the third 95 in our HIV clinics: it is possible, but there is still a lot to do	Elisabetta Teti, Roma
490	OC 55	Implementation of the Regional DCA 401/2016 in Latium: an example of a coordinated, multidisciplinary and individualized approach to PLWH territorial healthcare, forerunner of the National Recovery and Resilience Plan (PNRR) indications	Augusto Faticoni, Roma
105	OC 56	BELONG – Why people living with HIV must be included in non-HIV Clinical Trials. A community-led initiative for an inclusive approach to clinical research	Rocco Pignata, Bruxelles



Elenco Oral Communications

ID	N. pgm	Title	Presenting Author
15/06/2023 14.30 - 15.30 Cardiovascular and malignancies			
460	OC 57	Malignancies and MACEs in the PRESTIGIO Registry	Tommaso Clemente, Milano
114	OC 58	Cardiovascular events on integrase strand-transfer inhibitors treatment	Paolo Bonfanti, Monza
208	OC 59	Multidimensional evaluation of switching from a first generation 3 drug (DR) INSTI regimen to a second generation 3DR- or 2DR INSTI regimen: a single Center retrospective Desirability of Outcome Ranking (DOOR) analysis	Nicolò de Gennaro, Bari
46	OC 60	Selected comorbidities and the risk of ART switch in the context of HIV-RNA suppressed to ≤ 50 copies/mL	Alessandro Cozzi-Lepri, London
15/06/2023 15.35 - 16.35 Severe clinical issues in HIV-1 infection			
470	OC 61	Lower AIDS-related hospitalizations in women living with HIV multidrug resistance: results from the PRESTIGIO registry	Rebecka Papaioannu Borjesson, Milano
175	OC 62	Malignancies in PLWH: a 20-year experience in Perugia and Ancona hospitals	Laura Curci, Perugia
113	OC 63	Clinical presentation and neuroimaging in newly diagnosed AIDS patients in the last 6 years	Luciano Carani, Torino
355	OC 64	Prolonged survival in HIV-associated progressive multifocal leukoencephalopathy (PML) treated with Pembrolizumab: a case series on treatment and long-term follow-up	Marta Chiuchiarelli, Roma
15/06/2023 15.35 - 16.35 Oral or injectable 2-drug regimens			
399	OC 65	"With age comes wisdom": efficacy and tolerability of dolutegravir+lamivudine in virologically-suppressed PLWH	Gianmaria Baldin, Roma
440	OC 66	Assessing long-term risk of virological failure in PLWHIV starting dolutegravir +lamivudine as a switch strategy	Arturo Ciccullo, L'Aquila
391	OC 67	Characteristics and clinical features of patients receiving LA CAB/RPV in a large clinical centre	Maria Vittoria Cossu, Milano
37	OC 68	3-month outcome of long-acting cabotegravir and rilpivirine: preliminary results from the SCohoLART Study	Nicola Gianotti, Milano
15/06/2023 15.35 - 16.35 Prevention, access and engagement			
331	OC 69	A nurse-led HIV/STI prevention program in a Voluntary Counselling and Testing site in the metropolitan area of Rome	Rozenn Esvan, Roma
75	OC 70	Epidemiological impact of pre-exposure prophylaxis in HIV prevention: a single center observational experience in pre and post prophylaxis era	Leonardo Francesco Rezzonico, Milano
97	OC 71	Late HIV diagnosis: the new consensus definition reduces the proportion of late presentations	Vincenza Regine, Roma
227	OC 72	Impact of COVID-19 pandemic on retention in care of native and migrant PLWH in the ICONA cohort	Roberta Gagliardini, Roma
15/06/2023 16.40 - 17.50 The increasing burden of STIs			
396	OC 73	A cross sectional study of sexually transmitted infections in a northern Italy STI clinic	Daniele Tesoro, Milano
345	OC 74	Sexually Transmitted Infections In Men With Multidrug-Resistant Human Immunodeficiency Virus: Data From The PRESTIGIO Registry	Tommaso Clemente, Milano
474	OC 75	Temporal trends in incidence of bacterial sexually transmitted infections among PrEP users of Milano Checkpoint	Alessandro Tavelli, Milano
392	OC 76	Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae isolates between 2012 and 2023: a single-center experience in Milan, Italy	Maria Francesca Lucente, Milano
445	OC 77	Predictors of mpox duration and severity in an Italian multicenter cohort (Mpox-ICONA)	Valentina Mazzotta, Roma



Elenco Oral Communications

ID	N. pgm	Title	Presenting Author
15/06/2023 16.40 - 17.50 Vaccine in frail patients			
83	OC 78	Pneumococcal vaccination coverage among people living with HIV before and after the implementation of an on-site vaccination service at an HIV clinic: a retrospective observational study	Martina Laura Colombo, Milano
170	OC 79	SARS-CoV-2 mRNA vaccination and viro-immunological changes in PLWH	Andrea Antinori, Roma
248	OC 80	Specific humoral and T-cell response to three doses of SARS-CoV-2 mRNA vaccine in solid organ transplant recipients	Mariasilvia Guardiani, Roma
252	OC 81	Humoral and cell-mediated immune responses in elderly residing in a retirement house after 4 doses of anti-SARS-CoV-2 BNT162b2 vaccine	Maciej Stanislaw Tarkowski, Milano
263	OC 82	Assessment of SARS-CoV-2 specific T-cell responses using an in-house interferon-g release assay (IGRA) in people with HIV	Livia Benedetti, Roma
15/06/2023 16.40 - 17.40 Clinical outcome of SARS-CoV-2 infection			
410	OC 83	Association between vaccination status and disease severity in patients (pts) hospitalized for COVID-19: data from a national reference hospital	Ilaria Mastrosera, Roma
183	OC 84	Anti-spike SARS-CoV-2 antibody titer and risk of clinical progression in patients with COVID19-related pneumonia	Luca Mezzadri, Monza
338	OC 85	Vaccination against SARS-CoV-2 after the natural infection, is associated with a reduced risk of late-onset thrombotic and cardiovascular events (18-months analysis, on the "Surviving-COVID" Cohort, Bergamo)	Fabiana D'Aloia, Bergamo
48	OC 86	Long-term assessment of anti-SARS-CoV-2 immunogenicity after a mRNA vaccine in PLWH	Alessandro Cozzi-Lepri, London
16/06/2023 10.35 - 11.35 Bench studies of viral infections			
157	OC 87	Prevalence and phenotypic susceptibility to doravirine of the HIV-1 reverse transcriptase V106I polymorphism in B and non-B subtypes	Federica Giammarino, Siena
271	OC 88	The in vitro effects of dolutegravir and bictegravir on musculoskeletal cells	Alessandra Cazzaniga, Milano
322	OC 89	Pharmacokinetics of First-line Antitubercular Drugs in People Living with HIV and Controls in a Therapeutic Drug Monitoring Registry	Veronica Pirriatore, Torino
278	OC 90	Extracellular vesicles designed to decoy or compete with spike binding to the human ACE2 receptor of SARS-CoV-2 highlight the diversity of Omicron spike	Isabel Pagani, Milano
16/06/2023 10.35 - 11.35 Liver, vessels and lipids			
149	OC 91	To TAF or not to TAF? What is the difference? Data from a real-life setting	Nicola Squillace, Monza
27	OC 92	LDL-c target achievement in people living with HIV according to individual cardiovascular risk: a retrospective single center observational study	Giorgia Carrozzo, Milano
511	OC 93	Evaluation of intimal thickness and atheromatous plaques in HIV-experienced vs HIV-negative patients: data from the Archiprevalent cohort	Salvatore Martini, Napoli
510	OC 94	Risk factors for liver fibrosis progression in HIV: a multi-center longitudinal study	Jovana Milic, Modena
16/06/2023 10.35 - 11.35 PACS: what to asses			
514	OC 95	Assessing health status dynamics in people with post-acute COVID-19 syndrome comparing patient reported outcome measures with physical functioning, sarcopenia and frailty	Jovana Milic, Modena
299	OC 96	Frailty transitions in people with Post-Acute COVID Syndrome	Anna Spadoni, Modena
336	OC 97	12-month follow-up of the long COVID during three pandemic years	Irene Francesca Bottalico, Foggia
504	OC 98	A picture of psychological symptoms and coping strategies within post COVID-19 population	Anna Clelia Brita, Roma



Elenco Oral Communications

ID	N. pgm	Title	Presenting Author
16/06/2023 11.40 - 12.40 Innovative tools for diagnosis and monitoring of viral infections			
353	OC 99	Preliminary evaluation on the relevance of CSF cell-free mitochondrial DNA in different setting of viral neuroinflammatory diseases	Grazia Maria Liuzzi, Bari
281	OC 100	Serum Antibody Fingerprinting for SARS-CoV-2 Variants by Label-Free Microarray Biosensor	Alessia Lai, Milano
254	OC 101	Molecular diagnosis of human Monkeypox virus in the 2022 outbreak: preliminary evaluation of novel real-time qualitative PCR assays	Giulia Guarona, Genova
145	OC 102	Kinetic of TTV DNA load in peripheral blood lymphomonocytes in early treated acute HIV infections	Isabella Abbate, Roma
16/06/2023 11.40 - 12.40 The experience of PrEP in Italy			
72	OC 103	PrEP in Italy: increased coverage despite significant barriers to access	Marco Falaguasta, Padova
98	OC 104	Daily or On Demand Oral HIV Pre-exposure Prophylaxis: a Comparison of Users' Characteristics and Sexually Transmitted Infection Features	Caterina Quarta, Torino
235	OC 105	Confidence in the "Undetectable Equals Untransmittable" (U=U) paradigm among PrEP users	Serena Venturelli, Bergamo
449	OC 106	MDPV awareness and preparedness among PrEP users: a community survey	Alessandra Bianchi, Milano
16/06/2023 11.40 - 12.40 Virological topics in SARS-CoV-2 infection			
127	OC 107	A heparan sulfate proteoglycan binding tetrapeptide successfully inhibits SARS-CoV-2 Omicron replication	Camilla Biba, Siena
156	OC 108	Synergistic effects of antivirals and monoclonal antibodies in vitro against SARS-CoV-2 Wild Type B.1 strain and BQ.1.1 Omicron sublineage	Lia Fiaschi, Siena
200	OC 109	In vitro modelling to monitor pathogenic implications of RSV and SARS-CoV-2 co-infection	Claudia Vanetti, Milano
229	OC 110	Efficacy and SARS CoV-2 viral decay in nasopharynx, saliva and plasma in high-risk vaccinated patients treated with monoclonal antibodies (mAb)	Tomaso Beringheli, Milano
16/06/2023 12.45 - 13.45 Education and knowledge to reduce the burden of HIV and STIs			
418	OC 111	Community based voluntary counselling and testing (CBVCT) services for HIV and other sexual transmitted diseases offered during the pandemic	Alessandra Nappo, Roma
349	OC 112	Knowledge, Attitudes and Practices regarding HIV and other Sexually Transmitted Infections among High School Students in Southern Italy: a cross-sectional survey	Alessandra Belati, Bari
190	OC 113	Knowledge reduces stigma and generates awareness. The experience of the #CHIVuoleconoscere project in Bergamo	Ilaria Mercurio, Bergamo
99	OC 114	Just LILA - A pilot project and promotional campaign to promote self-testing	Maria Luisa Cosmaro, Milano
16/06/2023 12.45 - 13.45 Real world evidence in different treatment setting			
153	OC 115	Adherence to and forgiveness to imperfect adherence of FTC/TAF/RPV	Franco Maggiolo, Bergamo
151	OC 116	Adherence to and forgiveness to imperfect adherence of B/F/TAF	Franco Maggiolo, Bergamo
529	OC 117	Antiretroviral therapy prescription in older people living with HIV: cross-sectional study on multidrug regimens (MDR) and less drug regimens (LDR) in GEPO cohort	Benedetta Fioretti, Brescia
455	OC 118	Reasons for choosing a doravirine (DOR) based versus an INSTI-based regimen in ART-naïve and ART-experienced patients in real-world setting: data from the Icona Cohort	Annalisa Saracino, Bari



Elenco Oral Communications

ID	N. pgm	Title	Presenting Author
16/06/2023 14.00 - 15.00 Body and mind			
350	OC 119	BMI vs body composition changes to predict metabolic outcomes in people with HIV	Mattia Simion, Modena
467	OC 120	Prevalence, incidence and risk factors for sarcopenic obesity in people with HIV	Samuele Cantergiani, Modena
103	OC 121	Plasma and CSF biomarkers of CNS involvement during primary HIV infection	Andrea Calcagno, Torino
244	OC 122	The effects of switching from dolutegravir/abacavir/lamivudine to bicitegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: 3-months findings from a randomized study	Barbara Rossetti, Grosseto
16/06/2023 14.00 - 15.00 PACS: clinical outcome			
234	OC 123	Long COVID phenotypes and association with SARS CoV-2 variants in the EUCARE-POSTCOVID study	Francesca Bai, Milano
305	OC 124	Implication of Human Endogenous Retroviruses in development, progression and long-term sequelae of COVID-19: towards a personalized medicine	Claudia Matteucci, Roma
351	OC 125	Impact of long-COVID on daily working activity in non-elderly patients: a cross sectional study	Annunziata Ilenia Ritacco, Bari
236	OC 126	Symptom clusters and risk factors for Long COVID syndrome in hospitalized patients at 6 months of follow up	Viola Cogliandro, Monza
16/06/2023 14.00 - 15.00 Viruses, resistance and drugs			
158	OC 127	Does NGS on HIV-1 DNA improve resistance assessment in highly treatment-experienced and multi-resistant individuals under virological control? An experience from the PRESTIGIO Registry	Daniele Armenia, Roma
297	OC 128	HIV-1 persistence in people living with HIV who started antiretroviral therapy in acute or chronic infection: insight into molecular mechanisms	Elena Bruzzesi, Milano
301	OC 129	Comparison of different interpretation tools for HIV-1 resistance detected through Next Generation Sequencing in Italian clinical routine	Daniele Armenia, Roma
17	OC 130	Pharmacokinetic of tecovirimat in plasma and semen of Mpox patients	Massimo Tempestilli, Roma
16/06/2023 14.00 - 15.00 Mpox and Immunopathogenic mechanisms			
282	OC 131	Humoral and cellular immune response after eight months from Mpox virus infection	Eleonora Cimini, Roma
480	OC 132	Neutralizing and T cell immunogenicity after MVA-BN vaccination for mpox according to previous smallpox vaccination, HIV status, and administration route	Valentina Mazzotta, Roma
87	OC 133	Interferon-gamma (IFN-g), But Not Tumor Necrosis Factor-alpha (TNF-a) Induces the Polarization of Human Monocyte-Derived Macrophage (MDM) into M1 Cells Restricting HIV-1 Replication	Chiara Mazzei, Milano
279	OC 134	Effect of sera from HIV-1-exposed seronegative subjects, long term non progressors, HIV-1+ and HIV-1- individuals on CCR5 expression and R5 HIV-1 infectivity in human primary macrophages and CD4+ T lymphocytes	Iole Farina, Roma



Elenco Oral Communications

ID	N. pgm	Title	Presenting Author
16/06/2023 15.05 - 16.05 Outcomes in treatment experienced PLWH			
251	OC 135	Effectiveness of switch to bicitgravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppressed persons living with HIV (PLWH): 96-week data from the Icona cohort	Antonella d'Arminio Monforte, Milano
525	OC 136	Effectiveness of bicitgravir/emtricitabine/tenofovir alafenamide(BIC/FTC/TAF) as switch strategy in virologically suppressed: real world data from monocentric cohort	Alberto Borghetti , Roma
230	OC 137	Use of tenofovir alafenamide/emtricitabine/bicitgravir (B/F/TAF) in treatment-experienced people living with HIV. Real-life data from Infectious Disease Unit of Alessandro Manzoni Hospital in Lecco	Federico Conti, Lecco
212	OC 138	Safety and efficacy of doravirine-based regimens in People Living With HIV: a real-life multicentric study	Ilenia Russotto, Messina
16/06/2023 15.05 - 16.05 Clinical approach to COVID in vulnerable populations			
84	OC 139	Efficacy and safety of therapies for COVID-19 in pregnancy: a systematic review and meta-analysis	Giacomo Guido, Bari
473	OC 140	SARS-CoV2 infection in patients with Hematological Malignancies in the omicron era: hospitalization, need for mechanical ventilation and mortality in seronegative and seropositive population	Valentina Menozzi, Modena
79	OC 141	Antibody response in women vaccinated against SARS-CoV-2 during pregnancy and respective babies at birth and after a nine-months follow-up	Stefano Agliardi, Milano
492	OC 142	Safety of Antiviral therapy in fragile SARS COV 2 paediatric patients	Stefania Bernardi, Roma
16/06/2023 15.05 - 16.05 Emerging issues in HIV-1 infection			
414	OC 143	Impact of COVID-19 in time to linkage to care (Ltc) and ART initiation in the ICONA cohort	Pierluca Piselli, Roma
383	OC 144	Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the Icona network	Andrea Giacomelli, Milano
26	OC 145	Patient reported outcomes in older people living with/without HIV in the GEPO cohort	Andrea Calcagno, Torino
337	OC 146	Implementing an Electronic Patient-Reported Outcomes (ePROs) system in PLWH management: experience of Icona cohort	Alessandro Tavelli, Milano
16/06/2023 15.05 - 16.05 Novel clinical and epidemiological aspects of viral hepatitis			
269	OC 147	HCV replicative activity parallels the production of the three HBsAg forms (Large, Middle and Small HBsAg) and its pathogenetic impact is exacerbated by concomitant HBV replication	Leonardo Duca, Roma
446	OC 148	Management of antiviral prophylaxis in patients with resolved HBV infection receiving immunosuppressive treatment	Chiara Sorace, Roma
243	OC 149	HCV infection is stable in Central Italy across the last two decades and is characterized by the circulation of multiple HCV sub-genotypes 1 with a different pro-inflammatory potential	Romina Salpini, Roma
327	OC 150	Prevalence and outcome of Hepatitis Delta virus (HDV) infection among Persons Living with HIV (PLWH) in Italy: the Delta-Icona study	Antonella d'Arminio Monforte, Milano